Navigation Links
University of Maryland School of Medicine researchers find potential novel treatment for influenza
Date:5/1/2013

An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to University of Maryland School of Medicine researchers publishing in the journal Nature on May 1. The scientists found that a drug called Eritoran can protect mice from death after they have been infected with a lethal dose of influenza virus. The potential value of this drug as single therapy or in combination with antivirals is further supported by previous research that found that it is safe for use in humans. The findings are of particular interest to scientists now that the latest deadly strain of flu, H7N9, is spreading in China 82 people in China had been infected with the new strain of flu virus as of April 26, and 17 had died.

Previous scientific studies have revealed that acute lung injury caused by the influenza virus is the result of an immune reaction mediated by a protein called Toll-like receptor 4 (TLR4). Senior author Stefanie Vogel, Ph.D., Professor of Microbiology and Immunology and Medicine at the University of Maryland, and colleagues previously demonstrated that mice that lack the ability to signal through TLR4 are highly refractory to influenza-induced lethality. In their new study, they extend these findings by showing that Eritoran a synthetic inhibitor of TLR4, originally developed by Eisai Inc. for treatment of sepsis improved clinical symptoms and prevented death when administered up to six days after infection with the influenza virus. Existing antiviral medications must be administered within two days of infection to be optimally effective.

Annual influenza epidemics are estimated to result in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths yearly worldwide. The virus is continually evolving and new variants give rise to seasonal outbreaks. Increasing resistance to existing antiviral therapies and the short time-frame in which thes
'/>"/>

Contact: Karen Robinson
krobinson@som.umaryland.edu
410-706-7590
University of Maryland Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. University of Houston study shows BP oil spill hurt marshes, but recovery possible
2. University of Alberta led research may have discovered how memories are encoded in our brains
3. BGI, University of Helsinki and Wuhan University sign a MOU concerning cooperation on genomics
4. Marshall University study may lead to new treatments for prostate cancer
5. University leads £6 million EU project to tackle obesity
6. A University of Tennessee professors hypothesis may be game changer for evolutionary theory
7. Life expectancy may affect when you get married, divorced, have kids: Queens University study
8. University of Toronto biologists predict extinction for organisms with poor quality genes
9. University of Minnesota invention helps advance reliability of alternative energy
10. Israel names Tel Aviv Universitys Renewable Energy Center a Center of Research Excellence
11. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
(Date:12/19/2014)... LaunchKey , the first decentralized mobile authentication and authorization ... era, today announced the close of $3 million in ... Metamorphic Ventures with participation from ENIAC Ventures, Crosslink Capital, ... has raised $4 million to date, and will use ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... of the body,s chemistry is controlled by the brain from ... recently in Developmental Cell , a team of scientists led ... exact structure of one crucial brain area in which biochemical commands ... there to the body. In the process, they discovered a surprising ...
... Seoul, S. Korea One of the most common ... targeted in a new collaborative venture between the internationally-renowned ... Korean arm of the leading global healthcare company, Sanofi-Aventis ... high throughput assay to screen IP-K,s chemical libraries for ...
... Mass., Nov. 2, 2011 VeCommerce Incorporated, a ... the recent completion of a management buyout from ... business as SimplySay, specializes in communications and speech ... services, insurance, and pari-mutuel wagering. ...
Cached Biology News:A hormone ensures its future 2Institut Pasteur Korea and Sanofi open a new research collaboration to combat HBV 2Institut Pasteur Korea and Sanofi open a new research collaboration to combat HBV 3VeCommerce Inc. Becomes SimplySay 2
(Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)...  Derma Sciences, Inc. (Nasdaq: DSCI ), ... care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic allografts ... the Premier, Inc. Regenerative Skin Grafting contract portfolio. ... and AMNIOMATRIX® product lines, which continue to be ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... for cells and tissues  ("BioLife" or the "Company"), today ... Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... N.J., Nov. 19 Novo Nordisk Inc.,announced today ... Sciele,Pharma, Inc. to market Prandin(R) (repaglinide). Under the ... and, upon approval by,the US Food and Drug ... repaglinide/metformin fixed dose combination tablet) to,physicians in the ...
... for dental implants in Italy is ... less than other European countries, WALTHAM, Mass., Nov. 19 ... into an important,dental implant pricing trend in Europe. The average ... than that of dental implants sold,in Germany, France, and the ...
... healthcare in rural South ... welfare of its people, NEW YORK, Nov. 16 Sharon L. ... Chairman of the Board of,the American Friends of the Phelophepa Train (AFPT). ... work of,the AFPT Board, Archbishop Desmond Tutu and Ms. Leah Tutu in ...
Cached Biology Technology:Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R) 2Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R) 3Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market 2Deloitte Chairman of the Board Sharon L. Allen Named Chairman of the American Friends of the Phelophepa Train 2
... the benefits of a Hybridizer and UV Crosslinker ... , This unique, new design ... hybridization at one location , Hybridizer and ... each other , The Crosslinker is also ...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... Protein Phosphatase ( l-PPase) ... phosphatase with activity towards ... tyrosine residues. It is ... of the ORF221 open ...
... Analysis Note: Assays in Tris buffer, ... in the glycine buffer system. Assays in ... 5X that of the glycine buffer system. ... powder containing Tris-citrate buffer salts Preparation Unit ...
Biology Products: